ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2975

Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis

Bilgesu Ergezen1, Serdal Ugurlu2, Oguzhan Selvi3, Bugra Han Egeli4 and Huri Ozdogan3, 1Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 4Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Amyloidosis, Anakinra, canakinumab and familial Mediterranean fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: The most devastating complication of Familial Mediterranean Fever is secondary AA amyloidosis and is still a problem in many cases. Efforts have been paid to prevent AA amyloidosis or to control an already formed Amyloidosis in order to prevent organ function loss, particularly renal insufficiency. There are emerging therapies in FMF related amyloidosis. Here is aimed to evaluate the role of anti-IL-1 regimens, Anakinra and Canakinumab regarding their efficacy and safety in FMF related amyloidosis.

Methods: In this single center study, 44 patients diagnosed with FMF and had a histologically proven diagnosis of amyloidosis, were exposed to anakinra or canakinumab. Patients who used anakinra less than one month and canakinumab less than 2 injections were not included in this review. For all patients recruited in this review, the indication for anti-IL-1 therapies was FMF-related amyloidosis and ongoing inflammation despite adequate colchicine treatment. Patients were questioned with regards to FMF related characteristics, comorbidities. MEFV gene status, laboratory measures, side events and therapy outcomes were tested and followed.

Results: Among 44 patients, 40 were initially treated with anakinra and 4 with canakinumab. Among 40 patients treated with anakinra initially, anakinra was switched to canakinumab due to allergic reactions or insufficient response in 15 patients. There are 16 patients still being treated with anakinra and 10 with canakinumab. In order to evaluate the efficacy of anti-IL-1 agents, the patients were divided into two groups with regards to their initial renal function. Patients with initial Creatinine level below 1.5 mg/dL when an anti-IL-1 drug was initiated were reviewed as Group 1 and the patients who initially had chronic renal insufficiency and Creatinine level above 1.5 mg/dL were defined as Group 2. The analysis of clinical outcome was then performed as summarized in Table 1-a and Table 1-b. The decrease in proteinuria is more modest (p=0.01) in Group 2 in comparison with Group 1 (p<0,01). At the time of this review 8 patients were still on hemodialysis. Three patients had renal transplantation.

Conclusion: In cases with FMF related AA amyloidosis, there is a need for sufficient inflammatory control. We suggest that anti-IL-1 therapies are effective and tolerable in amyloidosis. These agents are particularly effective when administered in initial stages of renal disease and the effect is less pronounced in case of an already formed renal insufficiency. The anti-IL-1 agents are generally well tolerated and the related side effects were mostly reversible.


Disclosure: B. Ergezen, None; S. Ugurlu, None; O. Selvi, None; B. H. Egeli, None; H. Ozdogan, None.

To cite this abstract in AMA style:

Ergezen B, Ugurlu S, Selvi O, Egeli BH, Ozdogan H. Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/anti-il-1-therapies-in-patients-with-familial-mediterranean-fever-related-aa-amyloidosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-il-1-therapies-in-patients-with-familial-mediterranean-fever-related-aa-amyloidosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology